GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sandoz Group AG (OTCPK:SDZNY) » Definitions » Short-Term Debt

Sandoz Group AG (Sandoz Group AG) Short-Term Debt : $269 Mil (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Sandoz Group AG Short-Term Debt?

Sandoz Group AG's Short-Term Debt for the quarter that ended in Dec. 2023 was $269 Mil.

Sandoz Group AG's quarterly Short-Term Debt increased from . 20 ($0 Mil) to Dec. 2022 ($184 Mil) and increased from Dec. 2022 ($184 Mil) to Dec. 2023 ($269 Mil).

Sandoz Group AG's annual Short-Term Debt increased from . 20 ($0 Mil) to Dec. 2022 ($184 Mil) and increased from Dec. 2022 ($184 Mil) to Dec. 2023 ($269 Mil).

Sandoz Group AG Short-Term Debt Historical Data

The historical data trend for Sandoz Group AG's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sandoz Group AG Short-Term Debt Chart

Sandoz Group AG Annual Data
Trend Dec22 Dec23
Short-Term Debt
184.00 269.00

Sandoz Group AG Quarterly Data
Dec22 Dec23
Short-Term Debt 184.00 269.00

Sandoz Group AG Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Sandoz Group AG Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Sandoz Group AG's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Sandoz Group AG (Sandoz Group AG) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sandoz Group AG (OTCPK:SDZNY) » Definitions » Short-Term Debt
Comparable Companies
XSWX:SFZN XSWX:PPGN ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 HKSE:03692 NBIX NSE:DIVISLAB BOM:500124 VTRS SZSE:000963 XPAR:IPN SHSE:600085 XTAE:TEVA SHSE:600196
Traded in Other Exchanges
SDZXF:USA SDZz:UK D8Y0:Germany SDZ:Switzerland
Address
Forum 1, Novartis Campus, Basel, CHE, CH-4056
Website
https://www.sandoz.com
Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $9 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006 as well as U.S.'s first biosimilar, Zarxio, in 2015. It currently has eight commercialized biosimilars in a number of markets and has over 20 assets in pipeline.

Sandoz Group AG (Sandoz Group AG) Headlines

From GuruFocus

Q3 2023 Sandoz Group AG Earnings Call Transcript

By GuruFocus Research • 02-14-2024

Q3 2023 Sandoz Group AG Earnings Call Transcript

By GuruFocus Research • 02-14-2024